Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 405

Sort by

Sort Order Select

Journal Articles

Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma

Blood (2025) 146 (2): 178–190.

https://doi.org/10.1182/blood.2024026622

Published: 2025

Includes: Supplemental data

Journal Articles

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Blood (2025) 146 (2): 167–177.

https://doi.org/10.1182/blood.2024026216

Published: 2025

Includes: Supplemental data

Journal Articles

Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+

Blood (2025) 146 (1): 89–103.

https://doi.org/10.1182/blood.2024025102

Published: 2025

Includes: Supplemental data

Journal Articles

Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma

Chandraditya Chakraborty, Srikanth Talluri, Moritz Binder, Eugenio Morelli, Jessica Encinas Mayoral, Sanika Derebail, Anil Aktas Samur, Charles Epstein, Kenneth C. Anderson, Masood Shammas, Mehmet K. Samur, Mariateresa Fulciniti, Nikhil C. Munshi

Blood (2025) 146 (1): 104–114.

https://doi.org/10.1182/blood.2024026588

Published: 2025

Includes: Supplemental data

Journal Articles

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

Aurore Perrot, Cyrille Touzeau, Jerome Lambert, Cyrille Hulin, Denis Caillot, Lionel Karlin, Bertrand Arnulf, Philippe Rey, Laurent Garderet, Margaret Macro, Martine Escoffre Barbe, Julie Gay, Thomas Chalopin, Romain Gounot, Jean-Marc Schiano, Mourad Tiab, Mohamad Mohty, Frederique Kuhnowski, Jean Fontan, Salomon Manier, Frederique Orsini-Piocelle, Laure Vincent, Sophie Rigaudeau, Xavier Leleu, Benjamin Hebraud, Laurent Flet, Jean-Valere Malfuson, Caroline Jacquet, Driss Chaoui, Nathalie Meuleman, Wajed Abarah, Lydia Montes, Riad Benramdane, Cecile Sonntag, Hacene Zerazhi, Alina Danu, Olivier Allangba, Mamoun Dib, Murielle Roussel, Sophie Cereja, Julien Depaus, Nicolas Branche, Helene Demarquette, Valentine Richez, Brieuc Cherel, Laurent Frenzel, Marie-Christiane Vekemans, Noemie Bigot, Herve Avet-Loiseau, Jill Corre, Philippe Moreau

Blood (2025) 146 (1): 52–61.

https://doi.org/10.1182/blood.2024026230

Published: 2025

Journal Articles

Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma

Blood (2025) 145 (26): 3124–3138.

https://doi.org/10.1182/blood.2024025643

Published: 2025

Includes: Supplemental data

Journal Articles

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy

Blood (2025) 145 (25): 3007–3014.

https://doi.org/10.1182/blood.2024026455

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma

Blood (2025) 145 (22): 2614–2629.

https://doi.org/10.1182/blood.2024024781

Published: 2025

Includes: Supplemental data

Journal Articles

Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma

Yakinthi Chrisochoidou, Andrea Scarpino, Salomon Morales, Shannon Martin, Sarah Bird, Yigen Li, Brian Walker, John Caldwell, Yann-Vaï Le Bihan, Charlotte Pawlyn

Blood (2025) 145 (22): 2630–2644.

https://doi.org/10.1182/blood.2024025861

Published: 2025

Includes: Supplemental data

Journal Articles

Classic hairy cell leukemia and concomitant smoldering myeloma

Husam Jum’ah, David Viswanatha

Blood (2025) 145 (21): 2533.

https://doi.org/10.1182/blood.2025028465

Published: 2025

Journal Articles

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma

Evangelos Terpos, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Ioannis V. Kostopoulos, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Vasiliki Spiliopoulou, Magdalini Migkou, Despina Fotiou, Foteini Theodorakakou, Efstathios Kastritis, Maria Gavriatopoulou, Ourania E. Tsitsilonis, Meletios-Athanasios Dimopoulos

Blood (2025) 145 (20): 2353–2360.

https://doi.org/10.1182/blood.2024027686

Published: 2025

Journal Articles

Myelodysplastic neoplasm with biallelic TP53 inactivation in a patient with plasma cell myeloma after cytotoxic therapy

Rong He, Dong Chen

Blood (2025) 145 (19): 2230.

https://doi.org/10.1182/blood.2024028288

Published: 2025

Journal Articles

Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma

Blood (2025) 145 (17): 1876–1889.

https://doi.org/10.1182/blood.2024025694

Published: 2025

Includes: Supplemental data

Journal Articles

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial

Blood (2025) 145 (16): 1780–1787.

https://doi.org/10.1182/blood.2024027342

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS

Blood (2025) 145 (15): 1658–1669.

https://doi.org/10.1182/blood.2024025897

Published: 2025

Includes: Supplemental data

Journal Articles

Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes

Blood (2025) 145 (15): 1645–1657.

https://doi.org/10.1182/blood.2024024965

Published: 2025

Includes: Supplemental data

Journal Articles

The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

Mun Yee Koh, Tae-Hoon Chung, Nicole Xin Ning Tang, Sabrina Hui Min Toh, Jianbiao Zhou, Tze King Tan, Leilei Chen, Wee Joo Chng, Phaik Ju Teoh

Blood (2025) 145 (11): 1164–1181.

https://doi.org/10.1182/blood.2024024429

Published: 2025

Includes: Supplemental data

Journal Articles

Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study

Blood (2025) 145 (9): 970–974.

https://doi.org/10.1182/blood.2024025624

Published: 2025

Includes: Supplemental data

Journal Articles

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Don Benson, Maria Chaudry, Noa Biran, Kaveri Suryanarayan, Cheryl Li, Yuyin Liu, Sabrina Collins, Xavier Parot, Jonathan L. Kaufman

Blood (2025) 145 (9): 944–955.

https://doi.org/10.1182/blood.2024026124

Published: 2025

Includes: Supplemental data

Journal Articles

Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis

Blood (2025) 145 (7): 732–747.

https://doi.org/10.1182/blood.2024025690

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma

Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+

Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy

Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma

Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma

Classic hairy cell leukemia and concomitant smoldering myeloma

Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma

Myelodysplastic neoplasm with biallelic TP53 inactivation in a patient with plasma cell myeloma after cytotoxic therapy

Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial

Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS

Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes

The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only